NVO vs NVS
Novo Nordisk A/S and Novartis AG, both Healthcare
Novartis AG is the larger company at $296B against $211B. Over the past year NVS returned +20% against -35% for NVO. The RyuScore puts NVO ahead, 88 against 74 out of 100.
| Figure | NVO | NVS |
|---|---|---|
| Last close | $38.62 | $144 |
| Market cap | $211B | $296B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 21.2 |
| 1-year return | -35% | +20% |
| 5-year return | -15% | +103% |
| RyuScoresector-relative, 1–10 | 88/100 | 74/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Novo Nordisk A/S
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.